読み込み中
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
終値時点
$1.08
+$0.01 · +0.93%
時間外
$1.08
$0.00 · 0.00%
10月9日 16:10 ET
日中の時刻はETです。市場データは遅延する場合があります。
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
日中レンジ
現在 $1.08
52週レンジ
現在 $1.08
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
44
適正価値
センチメント
58
まちまち
リスク
72
高リスク
モメンタム
21
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
日中レンジ
現在 $1.08
52週レンジ
現在 $1.08
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
